|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
135,531,000 |
Market
Cap: |
393.04(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.47 - $3.22 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xeris Biopharma Holdings is a pharmaceutical company. Co.'s primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. Co.'s products include: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and older; Keveyis, the U.S. Food and Drug Administration approved therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor used for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Prestrelski Steven |
Chief Scientific Officer |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(494,780) |
0 |
|
- |
|
Pieper Steven |
Chief Financial Officer |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(158,108) |
0 |
|
- |
|
Hecht Beth |
See Remarks |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(206,366) |
0 |
|
- |
|
Edick Paul R |
Chief Executive Officer |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(13,430) |
0 |
|
- |
|
Edick Paul R |
Chief Executive Officer |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(608,064) |
0 |
|
- |
|
Shannon John Patrick Jr |
See Remarks |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(263,829) |
0 |
|
- |
|
Johnson Kenneth Erland |
See Remarks |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(89,583) |
0 |
|
- |
|
Schmid John P. |
Director |
|
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,659) |
0 |
|
- |
|
Pieper Steven |
See Remarks |
|
2021-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
158,858 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2021-04-12 |
4 |
AS |
$4.07 |
$40,725 |
D/D |
(10,000) |
496,824 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
506,824 |
|
- |
|
Johnson Kenneth Erland |
See Remarks |
|
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
91,890 |
|
- |
|
Shannon John Patrick Jr |
See Remarks |
|
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
271,224 |
|
- |
|
Edick Paul R |
See Remarks |
|
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
225,000 |
636,134 |
|
- |
|
Hecht Beth |
See Remarks |
|
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
210,814 |
|
- |
|
Deutsch Barry M. |
See Remarks |
|
2021-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
208,090 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2021-01-13 |
4 |
AS |
$6.01 |
$60,058 |
D/D |
(10,000) |
406,824 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2021-01-11 |
4 |
AS |
$5.72 |
$57,244 |
D/D |
(10,000) |
416,824 |
|
- |
|
Prestrelski Steven |
Chief Scientific Officer |
|
2020-12-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
426,824 |
|
- |
|
Edick Paul R |
See Remarks |
|
2020-12-09 |
4 |
B |
$4.06 |
$40,551 |
D/D |
10,000 |
411,134 |
2.81 |
- |
|
Hecht Beth |
See Remarks |
|
2020-06-30 |
4 |
A |
$2.26 |
$8,432 |
D/D |
3,731 |
60,814 |
|
- |
|
Shannon John Patrick Jr |
See Remarks |
|
2020-06-30 |
4 |
A |
$2.26 |
$8,432 |
D/D |
3,731 |
121,224 |
|
- |
|
Johnson Kenneth Erland |
See Remarks |
|
2020-06-30 |
4 |
A |
$2.26 |
$1,752 |
D/D |
775 |
26,890 |
|
- |
|
Deutsch Barry M. |
See Remarks |
|
2020-06-30 |
4 |
A |
$2.26 |
$8,432 |
D/D |
3,731 |
93,090 |
|
- |
|
Shannon John Patrick Jr |
See Remarks |
|
2020-05-13 |
4 |
B |
$3.55 |
$77,994 |
D/D |
22,000 |
117,493 |
2.74 |
- |
|
83 Records found
|
|
Page 1 of 4 |
|
|